Company intelligence / Profile preview

Neukio Biotherapeutics

Shanghai, Shanghai, Chinaneukio.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Neukio Biotherapeutics develops next-generation allogeneic cell therapies using induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T cells engineered with chimeric antigen receptors (CARs). Their lead programs target solid tumors using scalable, off-the-shelf products enabled by proprietary gene-editing and manufacturing technologies. The company has rapidly advanced from founding in mid–2021 to having its first two candidates enter clinical trials by late–2024. No published human efficacy data yet; preclinical results support further development.

Therapeutic areas
OncologyImmunology
Modalities
Allogeneic cell therapyiPSC-derived CAR-NK cellsiPSC-derived CAR-T cellsGene-edited immune cell therapies
Industry
Biotech
02

Drug pipeline

2 assets

NEUK203-215

1

1 more asset in the full pipeline.

03

Partnerships

EdiGene (gene-editing technology collaboration)Tofflon Life Sciences (bioreactor technology partnership)

Beyond the preview

Go deeper on Neukio Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neukio Biotherapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call